Cancer Diagnostics Market – By Application, By Cancer Type, By End Use – Global Forecast, 2025 to 2034

Cancer Diagnostics Market Size

The global cancer diagnostics market size was valued at around USD 158.7 billion in 2024 and is estimated to grow at 9% CAGR from 2025 to 2034. Cancer diagnostics refers to all the methods, processes, and technologies that identify and diagnose the disease prior to its spread through the body. Accurate cancer diagnostics help the patient as the data point determines the type, location, and stage to initiate treatment. The explanation distinguishes the details of one subject from another.
 

The growth for the cancer diagnostics market has been on the alarming side due to the rising cases of cancer being registered across the world in millions every year. According to the World Health Organization (WHO), approximately 20 million new cancer case patient visits were recorded in 2022, while the deaths could be summed to 9.7 million cases still attributed to old registration. It is set to reach the timely increase predicted of 35 million in 2027, approximately about a 77 percent increase in the number of newly registered cancer patients by then.

The wide variation in the number of people each year adds fundamental value to the need to diagnose the disease at its earlier stages, hence advancing the cancer diagnostic technologies and eventually leading to more growth opportunities in the market. Such advanced technologies include performing scans and other imaging techniques along with nuclear medicine, pathology, and molecular biology.
 

Furthermore, technology advances have seen growth within third-world nations driving their economies stronger. There have been major shifts in tools used in diagnostics as investment ratios put into the healthcare sector have been increased in the past within the countries. The accessibility for such tools has gotten broader as molecular diagnostics, imaging technology, and telemedicine have made it easier to find the disease and diagnose it in its early stages.
 

Cancer Diagnostics Market Trends

• Numerous initiatives by governments and health organizations to raise awareness about cancer and lessen the burden of cancer are expected to foster the progress of the market.
   

• A specific campaign targeted by the Pan American Health Organization, St. Jude Children's Research Hospital, and Childhood Cancer International seeks to equip parents, caregivers, and health professionals in some parts of Latin America and the Caribbean with knowledge on the earliest warning signs of the leading childhood and adolescent cancers.
   

• Furthermore, February 15 is celebrated as International Childhood Cancer Day to promote support for suffering children. This day aims at promoting awareness among people about the most common forms of pediatric cancers, including lymphoblastic leukemia, Hodgkin's lymphoma, and retinoblastoma.
   

Cancer Diagnostics Market Analysis

Based on application, the market is divided into tumor biomarkers tests, imaging, biopsy, liquid biopsy, immunohistochemistry, and in situ hybridization. The imaging segment is further bifurcated into ultrasound and radiology, mammography, MRI scan, PET scan, CT scan, SPECT, and other imaging. The imaging segment dominated the market accounting for 63.6% of revenue share in 2024.
 

• The imaging segment indicates significant increase as the rising number of breast cancer screening and increasing awareness programs have led to several women getting tested for breast cancer.
   
• The introduction of technological innovations such as computer-aided images will help spot cancer in women with dense breast tissues, which in return will propel the size of the market to grow.

Based on cancer type, the cancer diagnostics market is bifurcated into bladder cancer, breast cancer, colon and rectal cancer, endometrial cancer, kidney cancer, leukemia, liver and lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, prostate cancer, thyroid cancer, and other cancer types. The liver and lung cancer segment accounted for a 18.4% market share in 2024 and is projected for significant growth to reach USD 65.5 billion by 2034.
 

• Prevalent factors such as improper diet, high levels of smoking and alcohol consumption, and other social behavior positional elements are some of the major growth inhibitors across the market. The sudden rise in the number of lung cancer patients across the globe is a result of heavy tobacco usage.
   
• Every year, tobacco causes around seven million deaths globally, according to the World Health Organization (WHO), which means tobacco is responsible for most of the deaths caused by smoking. Moreover, an estimated 80% of smokers are in developing or emerging economies.
   
• In addition, the population density of lung cancer is likely to boost the segment substantially in other emerging economies. The liver-lung cancer segment is expected to dominate due to the drastic rise of cancer on the world stage.
   
• In this regard, the rising occurrence of liver-lung cancer among the existing population will increase the need for cancer diagnosis.
   

Based on end use, the cancer diagnostics market is bifurcated into hospitals, diagnostic laboratories, diagnostic imaging centers, and cancer research institutes.
 

• Revenue share estimates for the hospital segment are expected to record a substantial increase during the forecast period owing to its sizeable revenue share in 2024.
   
• The widespread use of biopsy, mammography, and other technologically advanced devices for treating cancer is going to increase the rate of cancer diagnoses in hospitals.
   
• In addition to this, the high availability of skilled personnel to operate cancer diagnosis machines and other advanced machines, as well as other procedures performed in hospitals, is likely to strengthen the revenue of this segment even higher.

The U.S. cancer diagnostics market is projected to grow significantly, reaching USD 135 billion by 2034.

• The increasing prevalence of cancer in the U.S. is on the rise due to several factors, including an aging population, environmental hazards, and an unhealthy lifestyle that involves smoking.
   
• According to projections from the American Cancer Society estimates that in 2024 there will be approximately 2,001,140 new cancer cases and 611,720 deaths resulting from the disease, stimulating the demand for effective diagnostic tools.
   
• Thus, aforementioned factors are estimated to augment market growth.
   

The cancer diagnostics market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• There is an urgent need for effective diagnostic tools that can meet these alarming statistics while enabling new levels of cancer care. The groundbreaking advances in technologies such as genetics, NGS, liquid biopsies, and molecular diagnostics are increasing the chances of identifying cancer with accurate precision in its early stages.
   

Japan cancer diagnostics market is anticipated to witness lucrative growth between 2025 – 2034.
 

• In Japan, the personalized medicine trend appears to be picking up pace. Healthcare professionals are now gradually incorporating regimes that focus on the genetic and molecular details of individual patients, meaning there will be an ever-increasing need for accurate and dependable diagnostic tests. This development will be instrumental in improving treatment results for cancer patients.
   

The cancer diagnostics market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is becoming more conscious about the need for the timely installation of cancer and bios screening devices. Campaigns and activities such as the Ministry of Health’s National Campaign for Breast Cancer Awareness are meant to raise awareness about the risks of cancer and the need to carry out bios and cancer screening regularly. Thus, escalating the market growth.
   

Cancer Diagnostics Market Share

The market for cancer diagnostics is competitive, comprising major and small players. Investment funding in the development of advanced diagnostic technologies such as liquid biopsies, NGS, and AI-driven imaging is a key strategy for the market players. Also, cooperation with research institutions and healthcare providers is vital for the application of modern technologies and the growth of distribution, further facilitating firms to help in meeting the growing demand for non-invasive diagnostic and cost-effective solutions. The presence of legal and other measures to protect innovation alongside the reduction in market entry barriers fosters the position of the firms in an expanding market.
 

Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the cancer diagnostics industry include:

• Abbott Laboratories
• AB Sciex Pte
• Agilent Technologies
• Becton, Dickinson and Company
• Biocare Medical
• Biocartis
• Biomerieux
• Bio-Rad Laboratories
• Danaher Corporation
• F-Hoffmann-La Roche
• GE Healthcare
• Hologic
• Johnson & Johnson
• Koninklijke Philips
• Myriad Genetics
• QIAGEN
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific
   

• Roche is pioneering in the area of molecular diagnosis and personalized treatment of cancers, incorporated with sophisticated technologies such as the Cobas systems for automated high-volume biomarker cancer testing.
   
• Thermo Fisher Scientific is a prominent facilitator of precision oncology, regarding its portfolio of next-generation sequencing (NGS) platforms.
   
• Hologic focuses on the health of women and is an industry leader in the diagnosis of breast cancer with the aid of 3D mammography equipment. These are easily the best providers of breast cancer screening services due to their emphasis on digital imaging and early diagnosis.
   

Cancer Diagnostics Industry News:

• In March 2023, QIAGEN N.V. formed a strategic partnership with the global pharmaceutical company Servier to develop a companion diagnostic test for TIBSOVO. Through this agreement, QIAGEN aimed to create a real-time in vitro PCR test for treating the blood cancer acute myeloid leukemia (AML). This partnership reinforced QIAGEN's position as a key player in oncology diagnostics and aligned with its strategy to innovate in precision medicine.
   
• In January 2023, Agilent entered into an agreement with Quest Diagnostics, enabling providers and patients across the U.S. to access the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test. This collaboration supported Agilent's business expansion and drove significant revenue growth.
   

The cancer diagnostics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Application

• Tumor biomarkers tests
  • Imaging
  • Ultrasound and radiology
  • Mammography
  • MRI scan
  • PET scan
  • CT scan
  • SPECT and other imaging 
• Biopsy
• Liquid biopsy
• Immunohistochemistry
• In situ hybridization

Market, By Cancer Type

• Bladder cancer
• Breast cancer
• Colon and rectal cancer
• Endometrial cancer
• Kidney cancer
• Leukemia
• Liver and lung cancer
• Melanoma
• Non-hodgkin lymphoma
• Pancreatic cancer
• Prostate cancer
• Thyroid cancer
• Other cancer types           

Market, By End use

• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Cancer research institutes            

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia 
• Latin America 
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE